The FDA approved the first-ever mRNA-1345 vaccine (mRESVIA) for respiratory syncytial virus (RSV) for people ages 60 and ...
Pfizer (PFE) stock gains as lung cancer therapy, Lorbrena, shows promising results in reducing disease progression or death ...
The European Medicines Agency has recommended the use of Pfizer's gene therapy for a rare bleeding disorder called hemophilia ...
But the head of the FDA’s CBER office didn’t tip where the agency stands on potentially broadening use of Sarepta’s Duchenne gene therapy Elevidys.
Today, we take a look at three promising biotech names that currently trade under $10 a share. Read more to see a full review ...
Ultragenyx is gearing up to take its glycogen storage disease (GSD) treatment to regulators next year after the gene therapy ...
Current health news includes Pfizer's lung cancer drug Lorbrena potentially hitting $1 billion in sales by 2030, U.S.
This health news summary spotlights major developments in cancer treatments, regulatory actions on biotechnology, and the ...
The global cell and gene therapy market is experiencing significant growth, driven by technological advancements, increasing ...
Moderna Inc. gained US approval for its RSV vaccine in older adults, giving the biotech company a second product as it seeks ...
Agios Pharmaceuticals announced a $905 million purchase with Royalty Pharma —Pheon Therapeutics raised a $120 million Series ...
The European Medicines Agency has recommended the use of Pfizer's gene therapy for a rare bleeding disorder called hemophilia B, which typically requires regular infusions of a blood-clotting protein, ...